Wall Street analysts predict that OptimizeRx Co. (NASDAQ:OPRX) will report sales of $6.78 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for OptimizeRx’s earnings. The highest sales estimate is $6.88 million and the lowest is $6.63 million. OptimizeRx reported sales of $5.10 million during the same quarter last year, which indicates a positive year-over-year growth rate of 32.9%. The firm is scheduled to issue its next earnings report after the market closes on Wednesday, August 7th.

According to Zacks, analysts expect that OptimizeRx will report full year sales of $28.70 million for the current year, with estimates ranging from $28.45 million to $28.85 million. For the next year, analysts anticipate that the company will report sales of $37.79 million, with estimates ranging from $37.17 million to $38.41 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow OptimizeRx.

Separately, Zacks Investment Research raised OptimizeRx from a “hold” rating to a “strong-buy” rating and set a $16.00 price target on the stock in a research note on Tuesday, May 14th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $19.00.

In other news, major shareholder Awm Investment Company, Inc. sold 82,126 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $13.64, for a total transaction of $1,120,198.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

A number of large investors have recently added to or reduced their stakes in the business. Strs Ohio bought a new stake in OptimizeRx in the 2nd quarter valued at $51,000. BlackRock Inc. purchased a new stake in OptimizeRx in the 4th quarter valued at about $55,000. Atlantic Trust LLC purchased a new stake in OptimizeRx in the 2nd quarter valued at about $126,000. Westwood Management Corp IL purchased a new stake in OptimizeRx in the 1st quarter valued at about $127,000. Finally, Bank of America Corp DE lifted its position in shares of OptimizeRx by 15.8% in the 4th quarter. Bank of America Corp DE now owns 15,302 shares of the company’s stock worth $168,000 after purchasing an additional 2,084 shares during the period. Hedge funds and other institutional investors own 48.51% of the company’s stock.

Shares of NASDAQ OPRX opened at $15.05 on Friday. OptimizeRx has a 12 month low of $8.92 and a 12 month high of $18.39. The company has a market cap of $182.11 million, a P/E ratio of 301.00, a P/E/G ratio of 1.70 and a beta of 0.44. The stock has a 50 day simple moving average of $15.36. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.03.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Story: QQQ ETF

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.